RenalTech to test BetaSorb for chronic kidney failure
This article was originally published in Clinica
Executive Summary
RenalTech International has started a US trial of its BetaSorb blood-purification device in patients with end-stage renal disease. The trial will evaluate the device for selectively removing toxins from the blood that are not efficiently removed by conventional haemodialysis, says the company.